Dr. Reckamp on MK-2206 for the Treatment of EGFR Wild-Type NSCLC

Jul 28, 2014

In Partnership With:

Karen L. Reckamp, MD, discusses the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.

Karen L. Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, City of Hope, discusses the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.

One cohort on this study consisted of patients with EGFR wild-type disease who had previously responded to EGFR TKI therapy for at least 12 weeks. The other cohort on the study consisted of patients with EGFR mutant disease who had responded to EGFR TKI therapy for at least 12 weeks. Patients with EGFR wild-type disease saw an improvement in disease control rate when treated with MK-2206 in combination with erlotinib.

This combination may improve de novo resistance and may be beneficial for patients with EGFR wild-type disease.

Related Videos
View All
Related Content